PI3Kα is central to multiple cellular processes and oncogenic signaling, and somatic mutations in the PIK3CA gene contribute to the development and progression of various cancers. The authors note that currently available orthosteric PI3Kα inhibitors such as Alpelisib and Inavolisib have been launched clinically but can produce toxicities and side effects, which the authors attribute to inadequate selectivity for mutant PIK3CA proteins. This limitation motivated exploration of allosteric inhibitors as an alternative strategy to improve selectivity for mutant PI3Kα forms while potentially reducing off-target toxicity.
The reported program built on an allosteric inhibitor scaffold exemplified by STX-478. The research integrated scaffold hopping together with comprehensive structural modification to generate a novel series of allosteric PI3Kα inhibitors. Through iterative chemical design and optimization, the team sought to identify compounds that combined mutant-selective pharmacology with favorable safety and drug-like properties.
From the optimization efforts the authors selected a lead compound, designated 11f, which features a benzothiophene core scaffold. Compound 11f was highlighted as the lead allosteric PI3Kα inhibitor arising from this program and is presented by the authors as the principal candidate for further development against tumors bearing the PIK3CA H1047R mutation.
According to the abstract, compound 11f demonstrates high selectivity for the PIK3CA mutant protein, specifically the H1047R alteration. The authors report that 11f shows low inhibition of hERG and minimal inhibition of cytochrome P450 enzymes (CYP), findings the team cites as favorable safety and drug–drug interaction indicators. Full experimental details, including assay methods, numerical potency or selectivity ratios, and comparative data versus wild-type PI3Kα or reference inhibitors, were not reported in the PubMed abstract and would require consultation of the full text.
The authors state that compound 11f displayed excellent in vivo efficacy, along with good safety and no observable impact on insulin balance in the reported studies. These attributes are emphasized as distinguishing features relative to existing orthosteric PI3Kα inhibitors, which have been associated with metabolic disruptions. The abstract does not provide specific in vivo models, dosing regimens, efficacy endpoints, or quantitative safety data; those details are not reported in the source abstract and should be obtained from the full article for rigor.
The manuscript frames its approach in contrast to orthosteric PI3Kα inhibitors (for example, Alpelisib and Inavolisib) that are clinically available but may cause toxicities attributable to insufficient mutant selectivity. The allosteric mechanism and mutant-selective design are proposed as means to mitigate these liabilities, offering potentially improved therapeutic windows for patients with HR+/HER2- breast cancer harboring the PIK3CA H1047R mutation.
The authors report favorable preclinical safety indicators for 11f (low hERG and minimal CYP inhibition) and claim oral bioavailability. These properties support progression as a drug candidate, but complete ADME, toxicology, and clinical translation data are not included in the abstract. The conflict of interest disclosure indicates that one author, Biao Lu, has a pending patent (WO2024199430) assigned to Changchun Genescience Pharmaceutical Co Ltd. Other authors declared no known competing financial interests or personal relationships that could have influenced the work as reported in the abstract.
The authors conclude that compound 11f is a highly promising preclinical drug candidate for targeted therapy of PIK3CA H1047R mutant HR+/HER2- breast cancer, combining mutant selectivity, oral activity, favorable safety markers, and no effect on insulin homeostasis as summarized in the abstract. The PubMed abstract emphasizes the benzothiophene scaffold and an allosteric mechanism as key innovations. For full experimental methods, quantitative results, and comprehensive safety and pharmacokinetic profiles, readers should consult the full-text article (Eur J Med Chem. 2026;312:118879; DOI: 10.1016/j.ejmech.2026.118879).